Japan's Nikkei plunges as tech stocks hammered by AI, rate hike worries

By Reuters News

TOKYO, Oct 15 (Reuters) - Japan's Nikkei share average tumbled nearly 5% on Thursday, with tech stocks hit hard by media reports about distressed debt at US cloud-computing provider CoreWeave, while hot US inflation figures sparked fears of higher interest rates.

The tech-heavy Nikkei .N225 dropped 4.8% to 64,489.06 as of the midday recess, while the broader Topix .TOPX fell 2.5%.

Selling was concentrated among AI-linked stocks, with chip equipment makers Advantest 6857.T and Tokyo Electron 8035.T sliding 13.9% and 7.3%, respectively. AI-focused startup investor SoftBank Group 9984.T skidded 9.4%.

Overnight, a hotter-than-expected US CPI reading stoked bets that the Federal Reserve will need to raise rates earlier and keep them elevated longer, taking a toll on the highly leveraged tech sector. The US Nasdaq Composite .IXIC slumped 1.9% on Wednesday.

CoreWeave CRWV.O plunged more than 15%, even after the company's CEO said in an employee memo that its deal backlog is large enough to cover its debt obligations.

"Concerns have been raised that the financial health of AI-related companies may be deteriorating," said Nomura strategist Wataru Akiyama. "Consequently, concerns regarding AI capital expenditure and the profitability of the AI business have risen rapidly."

A standout winner on the day was pharmaceuticals, which was the Tokyo exchange's best-performing industry group .IPHAM.T, climbing 3.4% as investors rotated into the traditionally defensive sector. Sumitomo Pharma 4506.T was the Nikkei's biggest percentage gainer, up 13%.

Of the Nikkei's 225 components, 145 fell versus 80 that rose.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.